<DOC>
	<DOCNO>NCT00288054</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Radiation therapy use high-energy x-ray kill tumor cell . Giving docetaxel cetuximab together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel give together cetuximab radiation therapy treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>S0429 : Docetaxel , Cetuximab , Radiation Therapy Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Test feasibility toxicity combine cetuximab , weekly docetaxel , concurrent radiotherapy patient poor-risk stage III non-small cell lung cancer ( NSCLC ) . Secondary - Evaluate response rate ( confirm unconfirmed , complete partial ) well overall progression-free survival . - Correlate EGFR mutation , KRAS mutation , EGFR/HER2 gene copy number detect FISH , protein expression immunohistochemistry EGFR-HER signaling pathway , phosphorylation , proliferative marker , apoptotic marker , select oncogene marker , marker angiogenesis biopsied pre-treatment tumor tissue response survival outcome . - Explore possible association change plasma angiogenic factor ( VEGF , IL-8 , bFGF ) cytokine level ( IL-6 , IL-1α , ICAM , TGF-β , others ) risk treatment-related pneumonitis esophagitis . OUTLINE : Patients enrol sequentially 1 2 treatment group . - Cohort 1 : Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 . - Cohort 2 : Patients receive cetuximab group 1 follow docetaxel IV 15-30 minute day 8 , 15 , 22 course 1 day 1 , 8 , 15 , 22 course 2 . Initially , 27 patient enrol Cohort 1 . Once patient Cohort 1 discontinue treatment , toxicity rate acceptable per protocol specification , additional 27 patient enrol Cohort 2 . Treatment cohort repeat every 28 day 2 course absence disease progression unacceptable toxicity . All patient also undergo radiotherapy daily , 5 day week , begin day 8 course 1 continue course 2 ( approximately 7 week ) . Patients progressive disease receive cetuximab alone weekly . Treatment cetuximab alone continue absence disease progression 2 year . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 54 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven newly diagnose single , primary , bronchogenic stage IIIA select stage IIIB ( exclude malignant pleural effusion ) nonsmall cell lung cancer ( NSCLC ) one follow cellular type : Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Unspecified Histology cytology involve mediastinal supraclavicular node sufficient diagnosis separate primary lesion lung parenchyma clearly evident radiograph ( i.e. , second biopsy require ) Underwent positron emission tomography ( PET ) scan within past 42 day N2 N3 mediastinal disease PET scan OR enlarge node CT scan determine N2 N3 biopsy Measurable disease , define lesion accurately measure least one dimension ≥ 2 cm conventional technique ≥ 1 cm spiral CT scan Pleural effusion , ascites , bone lesion , laboratory parameter consider measurable disease No brain metastasis Malignant pleural effusion allow provided 1 follow true : Present mediastinoscopy exploratory thoracotomy AND pleural fluid transudate negative cytology Present exploratory stag thoracotomy AND pleural fluid either transudate exudate negative cytology Present CT scan decubitus chest xray AND deem small tap either CT scan ultrasound guidance PATIENT CHARACTERISTICS : Zubrod performance status 01 , meet ≥ 1 follow criterion OR Zubrod performance status 2 comorbidities meet 1 follow criterion : No comorbidities FEV_1 &lt; 2 L OR &lt; 1 L estimate contralateral FEV_1 ≥ 0.6 L DLCO &gt; 10 mL/mm Hg/min Albumin &lt; 0.85 time low limit normal Unintentional weight loss &gt; 10 % within past 6 month Controlled congestive heart failure , opinion investigator , may become decompensated due radiotherapy FEV_1 &lt; 2 L OR &lt; 1 L estimate contralateral FEV_1 ≥ 0.6 L Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Must provide prior smoke history Serum bilirubin normal Meets one follow criterion : Alkaline phosphatase ( AP ) ≤ 4 time ULN AND SGOT SGPT normal AP normal AND SGOT SGPT ≤ 2.5 time ULN No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission No pregnant nursing patient Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy curative surgery cancer No prior radiotherapy neck and/or thorax reason No prior therapy specifically target EGFR pathway No concurrent growth factor ( e.g. , filgrastim [ GCSF ] , epoetin alfa , pegfilgrastim ) amifostine No concurrent intensitymodulated radiotherapy No concurrent prophylactic mediastinal , contralateral hilar , supraclavicular lymph node radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>